Showing articles associated with Ervin Fodor
After receiving his DPhil in Pathology in 1995, Professor Fodor split his time between Mount Sinai School of Medicine New York and the Dunn School of Pathology. In 2002, he received an MRC Senior Non-Clinical Research Fellowship, followed by an RCUK Academic Fellowship, which allowed Fodor to set up his research group at the Dunn School.
What is your main area(s) of interest/expertise?
My research interests are centred on viruses, particularly influenza viruses, which are important human and animal pathogens causing widespread clinical and veterinary disease. My group focuses on the fundamental molecular mechanisms of influenza virus replication, aiming to understand the molecular determinants of host range and virulence of influenza viruses. By gaining further insights into the molecular aspects of influenza virus replication we hope to facilitate the development of novel strategies to combat influenza.
What are you working on right now?
Our lab is working with several academic and industrial collaborators to assess existing antivirals for their potential to inhibit the SARS-CoV-2 polymerase, essentially shutting down the virus’ ability to self-replicate. Our work will allow us to identify new candidates in this effort and aid the development of SARS-CoV-2 reagents. We’re currently gearing up to test a collection of polymerase inhibitor candidates on site.
Why is Oxford a good place to work in this field of research?
Our work in Oxford has drawn the attention of numerous collaborators around the world. Our current collaborators include more local groups such as Jonathan Grimes’ group at the Division of Structural Biology at the Nuffield Department of Medicine and AI drug discovery firm Exscientia.
Find out more about Ervin Fodor : https://www.path.ox.ac.uk/content/ervin-fodor
